A384 SLEEP, Volume 43, Abstract Supplement, 2020 B. Clinical Sleep Science and Practice VIII. Sleep and Medical Disorders 1010 INDIVIDUALS WITH METABOLIC SYNDROME AND UNRECOGNIZED SLEEP APNEA CAN BE IDENTIFIED BY AN EMPLOYER-SPONSORED HEALTHCARE PROGRAM AND AT-HOME SLEEP STUDY Iakoubova, O. A. Tong, C. H. Arellano, A. R. Bare, L. A. Fragala, M. S. Devlin, J. J. Birse, C. E. Nichols Institute, Quest Diagnostics, San Juan Capistrano, CA. Introduction: Obstructive sleep apnea (OSA) is common in in- dividuals with metabolic syndrome (MetS) and increases risk of cardiovascular (CVD) events. Once recognized, therapeutic inter- ventions can reduce OSA severity and associated CVD risk. Of the 25 million Americans with OSA, 80% are unaware of their disease. To facilitate and improve diagnosis of OSA, diagnostic devices for at-home OSA testing have been developed in clinical studies and approved by FDA. We evaluated an employer-sponsored healthcare outreach program and at-home OSA testing as a means of identifying individuals likely to have OSA and referring them into care. Methods: Nine-hundred individuals with MetS, positive OSA Berlin questionnaire score and no prior diagnosis of OSA, as de- termined by annual workplace screening and health claims, were invited to participate in the sleep program. Those who agreed to participate (9.9%) received a diagnostic device for at-home OSA testing. Apnea-hypoapnea index (AHI) results recorded on re- turned diagnostic devices were evaluated by a sleep specialist. A telephone consultation with a program physician then provided each participant with an explanation of test results and referral into care. Based on AHI we identified individuals with moderate (AHI 16-30) to severe (AHI >30) OSA and referred them to care. Results: Of the 89 participating individuals, 21% had 3 MetS com- ponents, 53% had 4 components, and 20% had 5 components; 30% were diabetic; 83% had hypertension; and >50% were obese. Moderate to severe OSA was diagnosed in 52 (58%) of parti- cipants. Of those, 50% had moderate OSA and 50%, had severe OSA. Among individuals with moderate to severe OSA, 29 (56%) had a physician consultation and were referred to treatment. Conclusion: A personalized employer-sponsored healthcare out- reach program identified individuals with unrecognized OSA and referred them into care. Support: 1011 SLEEP DURATION MODERATES THE ASSOCIATION BETWEEN NEXT-DAY PHYSICAL ACTIVITY AND PAIN INTENSITY AMONG WOMEN WITH FIBROMYALGIA Whibley, D. 1,2,3 Williams, D. A. 2 Clauw, D. J. 2 Kratz, A. L. 3 1 Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UNITED KINGDOM, 2 Chronic Pain & Fatigue Research Center, Ann Arbor, University of Michigan, MI, 3 Department of Physical Medicine and Rehabilitation, Ann Arbor, University of Michigan, MI. Introduction: Suboptimal sleep has been consistently associated with greater next-day pain intensity among women with fibro- myalgia. In contrast, associations between physical activity and same-day pain in this population are contradictory. Given this inconsistency, we aimed to determine whether the daily physical activity-pain association is modified by sleep parameters. Methods: This micro-longitudinal study used data collected using wrist-worn triaxial accelerometers over seven consecutive days by 44 adult women with fibromyalgia. Derived variables included sleep duration, sleep onset latency (SOL), wake after sleep onset (WASO), sleep efficiency (SE) and maximum daily physical activity count. Participants also completed digital diaries of refreshed sleep upon awakening (scale 0-100), and pain intensity (5x/day, scale 0-100). Multilevel linear regression models with interaction terms were used to investigate moderating effects of sleep on the next-day person-centered maximum physical activity-average pain intensity association. Results: The sample mean age was 44 (SD 14). A total of 304 days of data were available for analysis. Mean sleep duration was 471min(SD 66); mean SOL 10min(SD 10); mean WASO 31min(SD 17), and mean SE 90%(SD 5). Sleep duration moderated the next- day maximum physical activity-pain association (Wald statistic p=0.01). After nights of both shorter (<7 hours) and longer sleep (>8 hours), higher levels of next-day maximum physical activity (compared to the participant’s overall study average) were associ- ated with days of greater average pain. In contrast, after nights of 7-8 hours of sleep, higher levels of next-day maximum physical ac- tivity were associated with days of lower average pain. Conclusion: An association between higher maximum physical ac- tivity and lower levels of pain was only observed after nights of 7-8 hours sleep. Engaging in physical activity is recommended for fibromyalgia-related pain management. Optimizing sleep duration may be useful in minimizing physical activity-related pain in this clinical population. Support: DW is supported by a Foundation Fellowship Versus Arthritis. The study that provided data was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health (award number K01AR064275;PI:ALK). The Michigan Institute for Clinical & Health Research provided subject recruitment support through the UMHealthResearch.org website (MICHR:NIH award number UL1TR002240). 1012 UROLOGIC FEATURES RELATED TO THE FIRST UNINTERRUPTED SLEEP PERIOD (FUSP) IN NOCTURIA Monaghan, T. F. 1 Agudelo, C. W. 1 Rahman, S. N. 1 Michelson, K. P. 1 Lazar, J. M. 1 Everaert, K. 2 Weiss, J. P. 1 Bliwise, D. L. 3 1 SUNY Downstate Health Sciences University, Brooklyn, NY, 2 Ghent University Hospital, Ghent, BELGIUM, 3 Emory University School of Medicine, Atlanta, GA. Introduction: In nocturia, longer FUSP (time to first void) correl- ates with better quality sleep (Bliwise et al, JCSM 2015;11:53-5) and, with treatment, longer FUSP is associated with decreased nightly voids (Epstein et al, Neurourol Urodyn 2018;37:186-91). We examined urologic correlates of FUSP in an outpatient nocturia population without comorbidities (CHF, OSA, ESRD, diuretics). Methods: Participants (n=119; men) kept a home flow/volume diary, tracking clock time and quantity of each urination across a 24-hr period. FUSP was defined as time between going to bed and time of first void. We analyzed the urine volume at first noc- turnal void (FNVV) (i.e., at end of FUSP). We also analyzed all nighttime volumes and divided by reported hours of sleep to im- pute nocturnal urine production (NUP) (in ml/hr, classified as high [>90 ml/hr] [n=49] vs low [<90 ml/hr] [n=60])—a measure correl- ated with number of nocturia episodes (van Doorn et al, J Urol Downloaded from https://academic.oup.com/sleep/article/43/Supplement_1/A384/5846516 by guest on 10 January 2024